AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6351901
Drug: Oral atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral atenolol 50 mg once daily
Trial: 6351901
Drug: Oral atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral atenolol 100 mg once daily
Trial: 25066012
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod
Trial: 20142520
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (LT)
Trial: 10535718
Drug: carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carvedilol 25 mg
Trial: 10504599
Drug: Double‐blind intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double‐blind intradermal provocation/neutralization skin tests to food antigens
Trial: 1848721
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml 1% mepivacaine with pH raised to 7.25 by adding 4 ml 8.4% NaHCO3
Trial: 1848721
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml commercially prepared 1% mepivacaine hydrochloride solution containing 4 ml 0.9% NaCl (pH 6.0)
Trial: 31889433
Drug: Mixed hypoxic
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed hypoxic dose protocol (LHTLH)
Trial: 25936635
Drug: Propranolol (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (3.3 ± 3.0 mg/kg/day)
Trial: 21874537
Drug: Simvastatin 40-80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40-80 mg
Trial: 17934877
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) with agalsidase alfa infusions for > or = 18 months
Trial: 10611140
Drug: Eletriptan (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan (maximum blood concentration 0.5 microM after therapeutic dose)
Trial: 9360003
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg once daily)
Trial: 1559314
Drug: Diltiazem (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (4 times daily administration)
Trial: 28668558
Drug: Early rehabilitation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rehabilitation (exercise therapy) for 6 to 8 weeks
Trial: 20980920
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's Wort (SJW) 300 mg three times a day for 14 days in volunteers
Trial: 19526764
Drug: Sanhuang Qingxue
RxNorm normalized name: MENTHOL 4.3 g / METHYL SALICYLATE 9.4 g TOPICAL OIL [Shuang Long Pain Relieving Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanhuang Qingxue Yin (SQY) plus conventional Western medical therapy
Trial: 19526764
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medical therapy only
Trial: 17255240
Drug: Children treated
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children treated with antibiotics
Trial: 9706854
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg the first day followed by 100 mg per day
Trial: 9706854
Drug: Ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 800 mg per day
Trial: 9706854
Drug: Doxycycline plus
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline plus ibuprofen scheduled as in groups 1 and 2
Trial: 9706854
Drug: Placebo capsule/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule/day (control)
Trial: 8572869
Drug: Active antihypertensive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active antihypertensive treatment with dihydropyridine felodipine, with a focus on achieving DBP < or = 90 mmHg.
Trial: 8572869
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment before randomization.
Trial: 30874378
Drug: Suvorexant 20
RxNorm normalized name: suvorexant 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant 20 mg/d before bedtime for 2 weeks
Trial: 26066780
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus 12 sessions of individual music therapy (n = 15)
Trial: 26066780
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment only (n = 15)
Trial: 16075184
Drug: All antidepressants
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All antidepressants
Trial: 12834314
Drug: Extended anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended anticoagulant therapy (6 months for temporary risk factors or 1 year for idiopathic pulmonary embolism)
Trial: 12834314
Drug: Discontinue treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue treatment
Trial: 12834314
Drug: Discontinue treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue treatment (for idiopathic venous thromboembolism)
Trial: 8911976
Drug: Glibenclamide (2.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (2.5-20 mg)
Trial: 1725891
Drug: Nicardipine 40
RxNorm normalized name: niCARdipine 40 mg/200 mL-D5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 40 mg, twice daily
Trial: 1725891
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg, twice daily
Trial: 4002803
Drug: Oral muzolimine
RxNorm normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral muzolimine 120 mg
Trial: 26782031
Drug: 150 min/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 min/week of moderate-intensity aerobic exercise and twice-weekly supervised strength training
Trial: 24684838
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg quarterly ranibizumab
Trial: 24684838
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg quarterly ranibizumab
Trial: 24684838
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg monthly ranibizumab
Trial: 24684838
Drug: Loading phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading phase of ranibizumab therapy
Trial: 22669289
Drug: TAK-875 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 (25, 50, 100, 200, or 400 mg, orally, once daily for 14 days)
Trial: 15851648
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with beta-blocker (metoprolol)
Trial: 15851648
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with angiotensin-converting enzyme inhibitor (ramipril)
Trial: 15851648
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with dihydropyridine calcium channel blocker (amlodipine)
Trial: 10087825
Drug: Propofol anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anesthesia with restricted dose of fentanyl (20 micrograms.kg‐1)
Trial: 24886409
Drug: High-dose OFS+P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose OFS+P (30 g/d)
Trial: 24886409
Drug: Low-dose OFS+P
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OFS+P (15 g/d)
Trial: 24886409
Drug: Control (maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (maltodextrin 15 g/d)
Trial: 22914998
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg daily for nine months
Trial: 16051946
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy‐General (FACT‐G)
Trial: 12477680
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg x kg(-1) of 1% propofol and 3 mg x kg(-1) of 2.5% thiopentone (P/T)
Trial: 12477680
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg x kg(‐1) of 1% propofol and 1 mg x kg(‐1) of lidocaine (P/L)
Trial: 8728349
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg three times a day for 6 days
Trial: 9853274
Drug: enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 20 mg o.d.
Trial: 1857482
Drug: atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 50 mg o.d.
Trial: 1857482
Drug: chlorthalidone 12.5
RxNorm normalized name: chlorthalidone 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorthalidone 12.5 mg o.d.
Trial: 6220870
Drug: Erythromycin 1.5
RxNorm normalized name: ERYTHROMYCIN 1.5% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 1.5 percent topical solution
Trial: 6220870
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1.0 percent topical solution
Trial: 31692212
Drug: Medication Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Management Review service (MMR)
Trial: 30159666
Drug: IgG anti-HEV
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG anti-HEV antibody testing
Trial: 23756585
Drug: Fortified milk
RxNorm normalized name: Fortified milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified milk (MG)
Trial: 19862820
Drug: Lenalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (25 mg/d on Days 1‐21 of a 28‐day cycle)
Trial: 17697909
Drug: Deferasirox (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (5 to 30 mg/kg per day)
Trial: 17697909
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (DFO) (20 to 60 mg/kg per day)
Trial: 7614647
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg.kg‐1 before CPB and before declamping of aorta)
Trial: 2517323
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg/day orally for 3 days, starting 1 day before X-ray examination)
Trial: 1013675
Drug: Metoprolol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (3 X 50 mg day)
Trial: 31439004
Drug: VIBRA model
RxNorm normalized name: doxycycline hyclate Oral Tablet [Vibra-Tabs]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIBRA model (differentiated ART delivery package with drug refills and follow-ups by trained village health workers, and SMS notifications)
Trial: 23538313
Drug: Combined periprostatic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined periprostatic nerve block (PPNB) and perianal‐intrarectal lidocaine‐prilocaine (PILP) cream
Trial: 23538313
Drug: Perianal‐intrarectal lidocaine‐prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perianal‐intrarectal lidocaine‐prilocaine (PILP) cream
Trial: 12919654
Drug: Glucocorticosteroid at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticosteroid at a low dosage
Trial: 12919654
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (with glucocorticosteroid)
Trial: 8956920
Drug: Levetiracetam (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (250 mg, 500 mg, 750 mg, 1,000 mg single oral dose; 250 mg b.i.d. for 3-5 days)
Trial: 7827348
Drug: Insulin management
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin management (infusion pump or split-dose therapy)
Trial: 3294081
Drug: Aluminum-magnesium antacid
RxNorm normalized name: ALUMINUM/MAGNESIUM HYDROXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum-magnesium antacid (120 mmol/day)
Trial: 3294081
Drug: Pirenzepine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (50 mg b.i.d.)
Trial: 31016613
Drug: Teriflunomide sodium
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Teriflunomide sodium 10 mg
Trial: 12242054
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg mifepristone
Trial: 15079120
Drug: Intraoperative intercostal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intercostal nerve blockade with alcohol plus postoperative epidural analgesia with morphine (n=27)
Trial: 15079120
Drug: Postoperative epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative epidural analgesia with morphine only (n=30)
Trial: 11199943
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium (valproate) augmentation with haloperidol
Trial: 11199943
Drug: Haloperidol alone
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol alone (no-augmentation group)
Trial: 11199943
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium (valproate) augmentation after 14 days (delayed-augmentation group)
Trial: 11199943
Drug: Early-augmentation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-augmentation group
Trial: 8676626
Drug: Acamprosate (1998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (1998 mg daily for bodyweight > 60 kg; 1332 mg daily for ≤ 60 kg)
Trial: 30695288
Drug: First-generation antipsychotic
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antipsychotic prescription
Trial: 30695288
Drug: Anticholinergic drug
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic drug administration
Trial: 29383596
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) at 5 mg/kg at 0, 2, and 6 weeks, followed by every 8 weeks for 2 years
Trial: 27629859
Drug: TDF/PI-48w (tenofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/PI-48w (tenofovir disoproxil fumarate 300 mg/day plus pegylated interferon 180 μg/week for 48 weeks)
Trial: 22989707
Drug: Oxytocin discontinuation
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin discontinuation (DC)
Trial: 19604092
Drug: Clozapine or
RxNorm normalized name: clozapine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine or Olanzapine (specific dosage not mentioned)
Trial: 17544778
Drug: 20‐mg anterior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20‐mg anterior sub‐Tenon injection of triamcinolone
Trial: 17544778
Drug: 20‐mg anterior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20‐mg anterior sub‐Tenon injection followed by focal photocoagulation after 4 weeks
Trial: 17544778
Drug: 40‐mg posterior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40‐mg posterior sub‐Tenon injection of triamcinolone
Trial: 17544778
Drug: 40‐mg posterior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40‐mg posterior sub‐Tenon injection followed by focal photocoagulation after 4 weeks
Trial: 14968084
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using verteporfin (Visudyne®)
Trial: 11403730
Drug: Nicotine 4-mg
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 4-mg gum + cigarette
Trial: 11403730
Drug: Nicotine 4-mg
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 4-mg gum + unlit cigarette
Trial: 11403730
Drug: Nicotine 4-mg
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 4-mg gum
Trial: 11403730
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups during exercise
Trial: 16398726
Drug: Granulocyte-colony-stimulating factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony-stimulating factor (G-CSF) mobilized prophylactic granulocyte transfusions (Cohort G)
Trial: 9415540
Drug: Total lymphoid
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total lymphoid irradiation plus low-dose prednisone (TLI-LDP)
Trial: 3316317
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg nickel sulfate taken once a week for 6 weeks
Trial: 3316317
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg nickel sulfate taken daily
Trial: 30021646
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg/100 mL)
Trial: 30021646
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl 100 mL)
Trial: 18765433
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg) plus Ezetimibe (10 mg)
Trial: 15990426
Drug: Galantamine prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine prolonged-release capsule (PRC) at doses of 16 or 24 mg/day
Trial: 15990426
Drug: Galantamine prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine prolonged-release capsule (PRC)
Trial: 12723400
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg per day of itraconazole (ITCZ)
Trial: 12723400
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg per day of itraconazole (ITCZ)
Trial: 10506042
Drug: Injection with
RxNorm normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection with 10 mg lignocaine and 40 mg methylprednisolone
Trial: 10506042
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 mg lignocaine)
Trial: 10506042
Drug: Non-responders in
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders in control group receiving 40 mg methylprednisolone
Trial: 9005799
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg twice a day for 5 days (IV for first 2 days, then oral for next 3 days)
Trial: 9005799
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg twice a day for 3 days (oral) + intravenous infusion of 200 mg twice a day for 3 days (for medium disease)
Trial: 9005799
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg twice a day for 5 days (for chronic carriers)
Trial: 9005799
Drug: Ofloxacin (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (dosage not specified)
Trial: 6751704
Drug: Budesonide ointment
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide ointment (treated under occlusive dressings for 1 week)
Trial: 6751704
Drug: Budesonide ointment
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide ointment (treated for 2 weeks)
Trial: 31395484
Drug: Alfaxalone CRI
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone CRI at 0.15 mg kg‐1 minute‐1 for 90 minutes (short CRI)
Trial: 31395484
Drug: Alfaxalone CRI
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone CRI at 0.15 mg kg‐1 minute‐1 for 180 minutes (long CRI)
Trial: 31395484
Drug: Alfaxalone bolus
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone bolus (3 mg kg‐1) followed by CRI